Clinical Trial

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-25; most recent amendment 2026-06-29.
Status change: Not Yet Recruiting → Recruiting 2026-04-16
Trial Details
NCT Number NCT06947941
Lead Sponsor Bristol-Myers Squibb
Conditions Alzheimer Disease, Psychosis
Enrollment 325 participants
Start Date 2026-03-25
Primary Completion 2028-02-21 (estimated)
Study Completion 2028-03-20 (estimated)
Updated on ClinicalTrials.gov 2026-06-30